References
Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191–202.
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al. (1993). Gain of function mutations in p53. Nat Genet 4: 42–46.
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ . (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsc70–p53 complex with an altered half-life. Mol Cell Biol 8: 531–539.
Halevy O, Michalovitz D, Oren M . (1990). Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250: 113–116.
Kim E, Deppert W . (2004). Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 93: 878–886.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deppert, W. Mutant p53: from guardian to fallen angel?. Oncogene 26, 2142–2144 (2007). https://doi.org/10.1038/sj.onc.1210276
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210276
- Springer Nature Limited
This article is cited by
-
Anti-Apoptotic NF-κB and “Gain of Function” mut p53 in Concert Act Pro-Apoptotic in Response to UVB+IL-1 via Enhanced TNF Production
Journal of Investigative Dermatology (2015)
-
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase
Neurological Sciences (2013)
-
Cross talk between stimulated NF-κB and the tumor suppressor p53
Oncogene (2010)